Professor Michael J Cork
BSc MB PhD FRCP
Clinical Medicine, School of Medicine and Population Health
Professor of Dermatology
Full contact details
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
I joined the University of Sheffield in 1991 as a lecturer in dermatology whilst continuing as a practising dermatologist for the NHS in Sheffield. I had previously been a Registrar in Dermatology at the Royal Hallamshire Hospital, Sheffield, and before that a Registrar in Respiratory General Medicine at Leeds General Infirmary.
I have been closely involved with research in many areas of dermatology; including Atopic Eczema(dermatitis), Psoriasis, Vitiligo and the Genetics of Skin Disease. My major current research work is aimed at identifying gene–environment interactions in the development of atopic dermatitis leading to skin barrier breakdown and the understanding of how topical agents interact with the skin barrier; using this information to enhance the treatment of atopic dermatitis.
I am currently Head of Sheffield Dermatology Research in the School of Medicine & Population Health at the University of Sheffield and am Honorary Consultant Dermatologist to both Sheffield Children´s Hospital NHS Foundation Trust and to Sheffield Teaching Hospitals NHS Foundation Trust; my time is evenly split between the University and the NHS.
- Research interests
-
My research interests are inflammatory skin disorders including: atopic dermatitis (atopic eczema), psoriasis, alopecia areata and vitiligo. The group which includes both clinical and non-clinical staff has identified genetic variants associated with all of these diseases.
Internationally, Sheffield Dermatology Research is one of the leading groups translating basic dermatological science into new treatments for the clinic. Examples include `Skin Protease Inhibitors´ and `Vitamin A Metabolic Pathway Inhibitors´. In 2001, with help from The Wellcome Trust, the group formed a `spin-out´ company called `Molecular SkinCare´, with the aim of developing these treatments.
Another major focus of the group is the effect of topical pharmaceuticals, cosmetics and oils on the structure and function of the skin barrier. Research in this area comprises investigation of the skin barrier defect associated with skin disorders such as atopic dermatitis, how skin barrier defects develop and how to treat or repair the skin barrier defect. This includes the determination of the effect of topical agents/products on the skin of volunteers visiting our clinical diagnostic `skin laboratory´, where we can measure specific properties of the skin barrier, non-invasively, using an array of specialised equipment. These results are then correlated with variants in the genes that determine the structure and function of the skin barrier.
Research conducted by Sheffield Dermatology Research is at the interface between the clinic, academia and industry. Work has been funded by charities, including: The Wellcome Trust, British Skin Foundation and Psoriasis Association; also by the Kuwait Ministry of Health; and by pharmaceutical/cosmetics companies; including Astellas, Johnson & Johnson and Stiefel-GSK.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 400(10356), 908-919.
- Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. The Lancet, 395(10228), 962-972.
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 375, 2335-2348. View this article in WRRO
- Development of stratum corneum chymotrypsin-like protease activity and natural moisturizing factors from birth to 4 weeks of age compared with adults. British Journal of Dermatology, 175(4), 713-720. View this article in WRRO
- The Effect of an Emollient Containing Urea, Ceramide NP, and Lactate on Skin Barrier Structure and Function in Older People with Dry Skin. Skin Pharmacology and Physiology, 29(3), 135-147. View this article in WRRO
- Olive Oil, Sunflower Oil or no Oil for Baby Dry Skin or Massage: A Pilot, Assessor-blinded, Randomized Controlled Trial (the Oil in Baby SkincaRE [OBSeRvE] Study). Acta Dermato Venereologica, 96(3), 323-330.
- Comparing the Effect of a Twice-weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis. Acta Dermato Venereologica, 95(6), 653-658.
- Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 134(4), 818-823.
- The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis.. Br J Dermatol, 170(4), 914-921.
- Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev..
- Randomized, Controlled Trial Evaluating a Baby Wash Product on Skin Barrier Function in Healthy, Term Neonates. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing. View this article in WRRO
- Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care.. Pediatr Dermatol, 30(1), 42-50.
- The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis.. Br J Dermatol, 165(2), 329-334.
- Epidermal barrier dysfunction in atopic dermatitis.. J Invest Dermatol, 129(8), 1892-1908.
- Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology. View this article in WRRO
Chapters
- Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders
- The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd..
Reports
All publications
Journal articles
- Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial.. J Dermatolog Treat, 35(1), 2296851.
- Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab. Archives of Dermatological Research, 316(10). View this article in WRRO
- LONG-TERM EFFICACY OF ABROCITINIB AS MONOTHERAPY OVER 96 WEEKS IN THE JADE CLINICAL PROGRAM. Annals of Allergy, Asthma & Immunology, 133(6), S100-S100.
- DUPILUMAB TREATMENT IMPROVES ATOPIC DERMATITIS SIGNS ACROSS ANATOMICAL REGIONS IN PATIENTS AGED 12–17 YEARS. Annals of Allergy, Asthma & Immunology, 133(6), S96-S97.
- Practicality, Validity and Responsiveness of Using the Proxy Version of the CHU-9D with Children Aged 2 to 5 Years. Value in Health, S1098-3015(24)02861.
- The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study. Journal of the American Academy of Dermatology, S0190-9622(24)02896.
- A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council. British Journal of Dermatology, ljae342.
- 52650 Dupilumab Treatment Shows Rapid and Consistent Improvement in Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 17 Years: Results From an Open-Label Extension Study. Journal of the American Academy of Dermatology, 91(3), AB189-AB189.
- 52909 MOISTURIZER WITH SKIN IDENTICAL LIPIDS RESTORES BARRIER FUNCTION IN ECZMEA-PRONE SKIN AND REDUCES SKIN SUSCEPTIBILITY TO IRRITANTS. Journal of the American Academy of Dermatology, 91(3), AB259-AB259.
- 53081 Dupilumab Treatment Provides Sustained Improvement in Skin Barrier Function, Clinical Outcomes, and Patient-Reported Outcomes in Patients Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis. Journal of the American Academy of Dermatology, 91(3), AB34-AB34.
- 52273 Dupilumab Provides Sustained Normalization of Skin Barrier Function in Children With Moderate-to-Severe Atopic Dermatitis. Journal of the American Academy of Dermatology, 91(3), AB34-AB34.
- 51363 Growth Analysis in Children Aged Less Than 12 Years with Moderate-to-Severe Atopic Dermatitis. Journal of the American Academy of Dermatology, 91(3), AB1-AB1.
- Effects of a pH-Regulating Emollient Cream in Mild Atopic Dermatitis Patients with Moderate Localized Lesions. Skin Pharmacology and Physiology, 1-10.
- 280 Children with atopic dermatitis respond more rapidly to dupilumab treatment in comparison to adolescents and adults. Journal of Investigative Dermatology, 144(8), S48-S48.
- Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials. Clinical and Translational Science, 17(8).
- A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. British Journal of Dermatology, ljae287.
- The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children – results from the TREAT trial. British Journal of Dermatology, ljae276.
- P086 The UK-Irish Atopic Eczema Systemic TherApy Register (A-STAR): baseline characteristics of the cohort. British Journal of Dermatology, 191(Supplement_1), i55-i56.
- P097 ‘Real-world’ Janus kinase inhibitor treatments in the UK-Irish A-STAR register: cohort profile and treatment outcomes. British Journal of Dermatology, 191(Supplement_1), i61-i62.
- P036 Dupilumab treatment normalizes skin barrier function in children aged 6–11 years with moderate-to-severe atopic dermatitis. British Journal of Dermatology, 191(Supplement_1), i30-i30.
- O03 Comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic eczema: results from the UK-Irish A-STAR register. British Journal of Dermatology, 191(Supplement_1), i2-i3.
- Long-term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Revue Française d'Allergologie, 64, 104044-104044.
- 549 - Laboratory parameters in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial. British Journal of Dermatology, 190(Supplement_2), ii47-ii48.
- Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 153(2), AB5-AB5.
- Tolérance et efficacité à long terme du tralokinumab chez des adolescents atteints de dermatite atopique modérée à sévère : analyse intermédiaire d’ECZTEND. Annales de Dermatologie et de Vénéréologie - FMC, 3(8), A363-A364.
- ASSOCIATION BETWEEN SKIN BARRIER DEVELOPMENT AND EARLY-ONSET ATOPIC DERMATITIS: A LONGITUDINAL BIRTH COHORT STUDY. Journal of Allergy and Clinical Immunology.
- Dupilumab safety and efficacy in a phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis. Dermatology and Therapy, 13, 2697-2719. View this article in WRRO
- Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. British Journal of Dermatology, ljad281.
- A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative. Clinical and Translational Allergy, 13(9). View this article in WRRO
- Emollients for preventing atopic eczema: cost‐effectiveness analysis of the BEEP trial. Clinical & Experimental Allergy. View this article in WRRO
- Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatology and Therapy, 13(9), 1987-2000. View this article in WRRO
- Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. British Journal of Dermatology, 189(5), 531-539.
- Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatment. Biomedical Optics Express, 14(8), 4126-4126.
- Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 159(6), 596-596.
- Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: post hoc analysis results from a phase III trial. American Journal of Clinical Dermatology, 24(5), 787-798. View this article in WRRO
- Are mild cleansers appropriate for hand hygiene in the COVID era? An in vitro investigation of the antiviral efficacy of different hand hygiene products. Frontiers in Virology, 3. View this article in WRRO
- Efficacy and safety of abrocitinib in patients with severe and/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial. American Journal of Clinical Dermatology, 24, 609-621. View this article in WRRO
- Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis. British Journal of Dermatology, 189(2), 238-240.
- Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. Journal of Dermatological Treatment, 34(1).
- Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology, 48(8), 881-888.
- Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis. Revue Française d'Allergologie, 63(3), 103434-103434.
- Dupilumab treatment in children aged 6–11 years with severe atopic dermatitis is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels. Revue Française d'Allergologie, 63(3), 103436-103436.
- Developing integrated care pathways for atopic dermatitis—challenges and unmet needs. Clinical and Translational Allergy, 13(3).
- Targeting skin barrier function in atopic dermatitis. The Journal of Allergy and Clinical Immunology: In Practice.
- Supplement Individual Article: The Importance of a Healthy Skin Barrier From the Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A Review and Consensus. Journal of drugs in dermatology : JDD, 22(2), s3-SF344607s.
- Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 151(2), AB149-AB149.
- Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Pediatric Drugs, 25, 67-77.
- REAL-TIME INFRARED Spectroscopic measurement of Natural Moisturising Factor. Journal of Investigative Dermatology.
- Efficacité et tolérance de l’abrocitinib selon le poids corporel : analyse poolée de 3 essais cliniques randomisés. Annales de Dermatologie et de Vénéréologie - FMC, 2(8), A342-A343.
- Résultats d’abrocitinib chez les patients atteints de dermatite atopique et d’asthme : analyse de l’essai JADE REGIMEN. Annales de Dermatologie et de Vénéréologie - FMC, 2(8), A335-A336.
- Emollients for prevention of atopic dermatitis; 5‐year findings from the BEEP randomised trial. Allergy.
- Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 400(10356), 908-919.
- Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 23(3), 365-383.
- Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innovations.
- Efficacy and safety of dupilumab in children aged 6–11 years with inadequately controlled severe atopic dermatitis: Results from an open-label extension trial up to 1 year. Revue Française d'Allergologie et d'Immunologie Clinique, 62(3), 321.
- Moisturizer therapy in prevention of atopic dermatitis and food allergy: to use or disuse?. Annals of Allergy, Asthma & Immunology.
- Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clinical and Experimental Dermatology. View this article in WRRO
- Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema‐prone, skin. British Journal of Dermatology. View this article in WRRO
- Impact de l’abrocitinib sur les démangeaisons, le sommeil, la douleur cutanée et le stress psychologique chez les patients présentant une dermatite atopique modérée à sévère : analyse poolée des essais JADE en monothérapie. Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A345-A346.
- Impact de l’abrocitinib sur la réponse vaccinale chez les adolescents présentant une dermatite atopique modérée à sévère recevant les vaccins courants contre la diphtérie, la coqueluche et le tétanos dans l’étude de phase III JADE TEEN. Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A354-A355.
- Induction par l’abrocitinib, arrêt de la thérapie et récupération de l’efficacité par traitement de secours chez les adolescents présentant une dermatite atopique modérée à sévère : analyse post-hoc de l’étude de phase 3 JADE-REGIMEN (NCT036227767). Annales de Dermatologie et de Vénéréologie - FMC, 1(8), A348-A348.
- Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. Allergy.
- Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis : an analysis of patient‐reported outcomes. Journal of the European Academy of Dermatology and Venereology.
- D040 INFECTIONS IN DUPILUMAB PEDIATRIC CLINICAL TRIALS IN ATOPIC DERMATITIS (AD) — A POOLED ANALYSIS. Annals of Allergy, Asthma & Immunology, 127(5), S16-S17.
- P193 DUPILUMAB DECREASES TOTAL AND ALLERGEN-SPECIFIC IGE IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD). Annals of Allergy, Asthma & Immunology, 127(5), S54-S55.
- P190 ABROCITINIB EFFICACY AND SAFETY BY BODY WEIGHT: POOLED ANALYSIS OF 3 RANDOMIZED CLINICAL TRIALS. Annals of Allergy, Asthma & Immunology, 127(5), S53-S54.
- Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatology and Therapy, 11, 1643-1656. View this article in WRRO
- Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials. Dermatitis, 32(1S), S81-S91.
- Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities. Allergy and Asthma Proceedings, 42(5), 425-431.
- Laboratory safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis : results from a phase III clinical trial. Pediatric Drugs, 23(5), 515-527.
- Imaging striae distensae : a comparison between PS-OCT and digital dermoscopy. Biomedical Optics Express, 12(6), 3296-3311. View this article in WRRO
- 484 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. Journal of Investigative Dermatology, 141(5), s84.
- Treatment outcomes of patients with atopic dermatitis (AD) treated with dupilumab through the early access to medicines scheme (EAMS) in the UK. Ulster Medical Journal, 90(2), 70-76.
- Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
- A predictive self-organizing multicellular computational model of infant skin permeability to topically applied substances. Journal of Investigative Dermatology.
- European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
- A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 35(2), 464-475. View this article in WRRO
- Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With Comorbid Allergic Rhinitis or Asthma. Journal of Allergy and Clinical Immunology, 147(2), AB28-AB28.
- Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study. Journal of Allergy and Clinical Immunology, 147(2), ab156.
- Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. British Journal of Dermatology.
- Le dupilumab améliore les signes et symptômes de dermatite atopique érythrodermique chez des patients adultes et adolescents – analyse poolée de sous-groupes. Annales de Dermatologie et de Vénéréologie, 147(12), A362-A362.
- 16818 An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. Journal of the American Academy of Dermatology, 83(6), AB71-AB71.
- 15413 Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. Journal of the American Academy of Dermatology, 83(6), AB39-AB39.
- ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology.
- P302 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT FOOD ALLERGIES. Annals of Allergy, Asthma & Immunology, 125(5), S40-S41.
- P500 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT COMORBID ALLERGIC RHINITIS. Annals of Allergy, Asthma & Immunology, 125(5), S46-S46.
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). British Journal of Dermatology.
- Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology.
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 396(10246), 255-266. View this article in WRRO
- Vehicles for atopic dermatitis therapies: more than just a placebo. Journal of Dermatological Treatment. View this article in WRRO
- An investigation of the skin barrier restoring effects of a cream and lotion containing ceramides in a multi-vesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 1. Dermatology and Therapy. View this article in WRRO
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology. View this article in WRRO
- Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. Journal of the American Academy of Dermatology.
- European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
- Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. The Lancet, 395(10228), 962-972.
- Diaper dermatitis prevalence and severity : global perspective on the impact of caregiver behavior. Pediatric Dermatology, 37(1), 130-136. View this article in WRRO
- 一项关于 dupilumab 治疗湿疹青少年患者的研究. British Journal of Dermatology, 182(1), e47-e47.
- A study of dupilumab in the treatment of adolescents with eczema. British Journal of Dermatology, 182(1), e30-e30.
- Genotype–phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosis. British Journal of Dermatology, 182(3), 729-737.
- Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study : the softened water for eczema prevention (SOFTER) trial. BMJ Open, 9(8). View this article in WRRO
- European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 33(9), 1644-1659.
- Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment. View this article in WRRO
- British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. British Journal of Dermatology, 180(6), 1312-1338.
- Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology. View this article in WRRO
- Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement. Journal of the European Academy of Dermatology and Venereology, 33(5), 807-815. View this article in WRRO
- Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology. View this article in WRRO
- British Association of Dermatologists' guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. British Journal of Dermatology, 181(1), 37-54.
- Response to “Comment on: ‘When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council’”. Journal of the American Academy of Dermatology, 79(2), e25-e26. View this article in WRRO
- Infant Skin Barrier, Structure, and Enzymatic Activity Differ from Those of Adult in an East Asian Cohort. BioMed Research International, 2018. View this article in WRRO
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. British Journal of Dermatology, 178(5), e366-e366.
- 杜匹鲁单抗结合伴随性局部皮质类固醇治疗对环孢素A应答不充分或不耐受或者在医学上不建议采用环孢素A治疗的过敏性皮肤炎成人患者:安慰剂对照随机阶段III临床试验(LIBERTY AD CAFÉ). British Journal of Dermatology, 178(5), e385-e385.
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology, 178(5), 1083-1101. View this article in WRRO
- British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. British Journal of Dermatology, 178(4), 839-853.
- Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography. Biomedical Optics Express, 9(4), 2001-2001. View this article in WRRO
- A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT). British Journal of Dermatology, 179(6), 1297-1306.
- The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects. Journal of Investigative Dermatology, 138(1), 68-77. View this article in WRRO
- Le dupilumab lors de dermatite atopique modérée à sévère : résultats groupés de deux études randomisées de phase III (SOLO 1 et 2). Annales de Dermatologie et de Vénéréologie, 144(12), S266-S267.
- P479 Dupilumab improves patient-reported outcomes in atopic dermatitis patients inadequately controlled, intolerant, or inadvisable for cyclosporine-A. Annals of Allergy, Asthma & Immunology, 119(5), S94-S95.
- British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. British Journal of Dermatology, 177(5), 1170-1201.
- When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 77(4), 623-633. View this article in WRRO
- The British Skin Foundation: 20 years of supporting dermatology research. British Journal of Dermatology, 177(3), 608-609.
- Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial.. Trials, 18(1), 343-343. View this article in WRRO
- Erratum to: Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. Dermatol Ther (Heidelb).
- Computational design of treatment strategies for proactive therapy on atopic dermatitis using optimal control theory. Royal Society of London. Philosophical Transactions A. Mathematical, Physical and Engineering Sciences, 375(2096). View this article in WRRO
- Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. Dermatology and Therapy. View this article in WRRO
- British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 177(3), 628-636.
- View this article in WRRO Biologic Treatments for Atopic Eczema: Anti IL-4 and IL-13 biologics. Exchange: National Eczema Society Members' Magazine(163), 11-18.
- British Association of Dermatologists’ guidelines for the management of contact dermatitis 2017. British Journal of Dermatology, 176(2), 317-329.
- British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. British Journal of Dermatology, 176(1), 20-43.
- Updated guidance for writing a British Association of Dermatologists clinical guideline: the adoption of the GRADE methodology 2016. British Journal of Dermatology, 176(1), 44-51.
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 375, 2335-2348. View this article in WRRO
- Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study. Journal of Allergy and Clinical Immunology, 138(5), 1715-1719.e4. View this article in WRRO
- A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. British Journal of Dermatology, 175(5), 1011-1019. View this article in WRRO
- Development of stratum corneum chymotrypsin-like protease activity and natural moisturizing factors from birth to 4 weeks of age compared with adults. British Journal of Dermatology, 175(4), 713-720. View this article in WRRO
- British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology, 175(1), 23-44.
- The Effect of an Emollient Containing Urea, Ceramide NP, and Lactate on Skin Barrier Structure and Function in Older People with Dry Skin. Skin Pharmacology and Physiology, 29(3), 135-147. View this article in WRRO
- Recommendations from a European Roundtable Meeting on Best Practice Healthy Infant Skin Care. Pediatric Dermatology, 33(3), 311-321. View this article in WRRO
- Olive Oil, Sunflower Oil or no Oil for Baby Dry Skin or Massage: A Pilot, Assessor-blinded, Randomized Controlled Trial (the Oil in Baby SkincaRE [OBSeRvE] Study). Acta Dermato Venereologica, 96(3), 323-330.
- Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 26(4), 306-315. View this article in WRRO
- Comparing the Effect of a Twice-weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis. Acta Dermato Venereologica, 95(6), 653-658.
- Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings. Cochrane Database of Systematic Reviews, 2014(12), 1-16.
- Wzmocnienie bariery skórnej środkami zmiękczającymi od urodzenia skutecznie zapobiega atopowemu zapaleniu skóry. Alergologia Polska - Polish Journal of Allergology, 1(4), T33-T41.
- Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 134(4), 818-823.
- The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis.. Br J Dermatol, 170(4), 914-921.
- Topical Treatments for Chronic Plaque Psoriasis. Journal of the American Academy of Dermatology(In Press).
- Topical treatments for chronic plaque psoriasis: An abridged Cochrane Systematic Review. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 69(5), 799-807.
- Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. BRITISH JOURNAL OF DERMATOLOGY, 169(3), 519-527.
- Use of emollients in dry-skin conditions: Consensus statement. Clinical and Experimental Dermatology, 38(3), 231-238.
- Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev..
- The effects of pimecrolimus on the innate immune response in atopic dermatitis.. Br J Dermatol, 168(2), 235-236.
- Optical coherence tomography demonstrates differential epidermal thinning of human forearm volar skin after 2 weeks application of a topical corticosteroid vs a non-steroidal anti-inflammatory alternative. Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 8565.
- Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme.. BMC Dermatol, 13, 7. View this article in WRRO
- Randomized, Controlled Trial Evaluating a Baby Wash Product on Skin Barrier Function in Healthy, Term Neonates. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing. View this article in WRRO
- Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care.. Pediatr Dermatol, 30(1), 42-50.
- Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: Assessor-blinded randomised controlled equivalence trial. BMC Pediatrics, 12. View this article in WRRO
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics. View this article in WRRO
- The Challenges and Realties of Diaper Area Cleansing for Parents. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 41(6).
- Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Human Molecular Genetics, 21(23), 5185-5192.
- Atopic dermatitis: A candidate for disease-modifying strategy. Allergy: European Journal of Allergy and Clinical Immunology.
- Patient education about topical treatments. BRITISH JOURNAL OF DERMATOLOGY, 165(6), 1159-1160.
- Patch testing is a useful investigation in children with eczema. CONTACT DERMATITIS, 65(4), 208-212.
- Baby skin care research programme: assessor-blinded randomised controlled trial comparing impregnated cleansing wipes with water in infants. Archives of Disease in Childhood - Fetal and Neonatal Edition, 96(Supplement 1), Fa43-Fa43.
- Aqueous cream damages the skin barrier.. Br J Dermatol, 164(6), 1179-1180.
- Infant skin-cleansing product versus water: A pilot randomized, assessor-blinded controlled trial. BMC PEDIATR, 11. View this article in WRRO
- The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis.. Br J Dermatol, 165(2), 329-334.
- Patch testing is a useful investigation in children with eczema.. Contact Dermatitis, 65(4), 208-212.
- HLA-C, CSTA and DS12346 susceptibility alleles confer over 100-fold increased risk of developing psoriasis: evidence of gene interaction.. J Hum Genet, 56(6), 423-427.
- Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. DERMATOLOGY, 222(1), 36-48.
- Use of oil for baby skincare: A survey of UK maternity and neonatal units. British Journal of Midwifery, 19(6), 354-362.
- The 3'-UTR AACCins5874 in the stratum corneum chymotryptic enzyme gene (SCCE/KLK7), associated with atopic dermatitis; causes an increased mRNA expression without altering its stability.. J Dermatol Sci, 61(2), 131-133.
- A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.. Nat Genet, 42(11), 985-990.
- Epidermal barrier dysfunction in atopic dermatitis.. J Invest Dermatol, 129(8), 1892-1908.
- Skin barrier breakdown: a renaissance in emollient therapy.. Br J Nurs, 18(14), 872-877.
- Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. J EUR ACAD DERMATOL, 23(7), 751-759.
- A qualitative study exploring women's and health professionals' views of newborn bathing practices. Evidence Based Midwifery, 7(4), 112-121.
- Topical treatments for chronic plaque psoriasis. COCHRANE DB SYST REV(2).
- The autoimmune regulator gene (AIRE) is strongly associated with vitiligo.. Br J Dermatol, 159(3), 591-596.
- Association analysis of the skin barrier gene cystatin A at the PSORS5 locus in psoriatic patients: evidence for interaction between PSORS1 and PSORS5.. Eur J Hum Genet, 16(8), 1002-1009. View this article in WRRO
- Therapeutic Implications of the Differential Effects of Topical Corticosteroids and Calcineurin Inhibitors on the Skin Barrier. Dermatitis, 19(4), 218-238.
- Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis.. Br J Dermatol, 159(1), 77-85.
- Genetic analysis of autoimmune regulator haplotypes in alopecia areata.. Tissue Antigens, 71(3), 206-212.
- Gene-environment interactions in atopic dermatitis. Drug Discovery Today: Disease Mechanisms, 5(1).
- A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis.. Allergy, 62(5), 514-519.
- An update on the safety and tolerability of pimecrolimus cream 1%: Evidence from clinical trials and post-marketing surveillance. DERMATOLOGY, 215, 27-44.
- The non-synonymous C1858T substitution in the PTPN22 gene is associated with susceptibility to the severe forms of alopecia areata.. Hum Immunol, 67(7), 535-539.
- New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions.. J Allergy Clin Immunol, 118(1), 3-21.
- Concerns over confidentiality may deter adolescents from consulting their doctors. A qualitative exploration.. J Med Ethics, 32(3), 133-137.
- Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. HUM MOL GENET, 15(4), 519-529.
- Interleukin-1: a key inflammatory mediator in psoriasis?. Cytokine, 33(2), 72-78.
- Safety and tolerability of 1% pimecrolimus cream among infants: Experience with 1133 patients treated for up to 2 years. PEDIATRICS, 117(1), E118-E128.
- Adverse effects of topical glucocorticosteroids. J AM ACAD DERMATOL, 54(1), 1-15.
- Predisposition to sensitive skin and atopic eczema.. Community Pract, 78(12), 440-442.
- The development of a preference-based measure of health in children with atopic dermatitis.. Br J Dermatol, 153(2), 372-377.
- MICROCEPHALY-LYMPHOEDEMA-CHORIORETINAL-DYSPLASIA SYNDROME WITH ATRIAL SEPTAL DEFECT. Pediatric Dermatology, 22(4), 373-374.
- Single-point haplotype scores telomeric to human leukocyte antigen-C give a high susceptibility major histocompatibility complex haplotype for psoriasis in a Caucasian population.. J Invest Dermatol, 124(3), 545-552.
- Consensus statement on the safety profile of topical calcineurin inhibitors. DERMATOLOGY, 211(2), 77-78.
- Genome-wide studies of psoriasis susceptibility loci: a review.. J Dermatol Sci, 35(3), 171-179.
- Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis.. J Invest Dermatol, 123(1), 62-66.
- Severe pruritus in a patient with urticaria pigmentosa treated with topical 5% urea and 3% polidocanol cream. Journal of Dermatological Treatment, 14(3), 190-191.
- Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse.. Br J Dermatol, 149(3), 582-589.
- Notch4, a non-HLA gene in the MHC is strongly associated with the most severe form of alopecia areata.. Hum Genet, 112(4), 400-403.
- Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety.. The Journal of dermatological treatment, 14(2), 71-85.
- An audit of adverse drug reactions to aqueous cream in children with atopic eczema. Pharmaceutical Journal, 271(7277), 747-748.
- Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis.. Tissue Antigens, 60(6), 489-495.
- Role of the autoimmune regulator (AIRE) gene in alopecia areata: Strong association of a potentially functional AIRE polymorphism with alopecia universalis. J INVEST DERMATOL, 119(3), 719-719.
- Tumour necrosis factor-alpha induced up-regulation of elafin and antileukoprotease enhances the skin barrier. J INVEST DERMATOL, 119(3), 729-729.
- Identification of known and novel genes whose expression is regulated by endogenous retinoic acid during early embryonic development of the mouse. Mechanisms of Development, 114(1-2), 205-212.
- Topical preparations for the treatment of psoriasis: a systematic review. BRIT J DERMATOL, 146(3), 351-364.
- Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction.. Eur J Immunogenet, 29(1), 25-30.
- Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL1-L1 in alopecia areata: Strong disease associations and possible gene interaction. J INVEST DERMATOL, 117(2), 431-431.
- Association analysis of IL1A and IL1B variants in alopecia areata.. Heredity (Edinb), 87(Pt 2), 215-219.
- Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region. Human Genetics, 106(6), 639-645.
- Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region.. Hum Genet, 106(6), 639-645.
- Topical preparations for the treatment of psoriasis: a systematic review. British Journal of Dermatology, 142(3), 351-364.
- Corrigendum: Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis (Human Molecular Genetics (2000) 8 (1135-1140)). Human Molecular Genetics, 9(4), 659.
- Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. BRIT J DERMATOL, 142(1), 52-58.
- Corneodesmosin (MHC S) gene in guttate psoriasis.. Lancet, 354(9178), 597.
- Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis.. Hum Mol Genet, 8(6), 1135-1140.
- Genetic association between MHC S gene and susceptibility to psoriasis. J INVEST DERMATOL, 112(4), 591-591.
- Genetic susceptibility and disease behaviour in Crohns disease: The role of tumour necrosis factor alpha gene promoter polymorphisms. GUT, 44, A29-A29.
- The tumor necrosis factor alpha gene promoter polymorphisms and Crohns disease: Study of genetic suscepibility and disease behavior. GASTROENTEROLOGY, 116(4), A678-A678.
- Treatment of psoriasis: day care vs. inpatient therapy. BRIT J DERMATOL, 140(2), 375-376.
- Taking the itch out of eczema: How the careful use of emollients can break the itch-scratch cycle of atopic eczema. Asthma Journal, 4(3), 116-120.
- Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo.. Br J Dermatol, 140(1), 73-78.
- A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. BRIT J DERMATOL, 139(4), 660-664.
- Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J INVEST DERMATOL, 110(3), 301-302.
- The importance of skin barrier function. J DERMATOL TREAT, 8, S7-S13.
- Cytokine dermatosis: Reactivation of eczema during interleukin-2 infusion. BRIT J DERMATOL, 136(4), 644-645.
- Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. BRIT J DERMATOL, 136(1), 147-148.
- Genetic control of cytokines. Cytokine gene polymorphisms in alopecia areata.. Dermatol Clin, 14(4), 671-678.
- Promoter region polymorphism in the human TNF-alpha gene is not associated with lichen sclerosus.. Exp Dermatol, 5(4), 227-229.
- The role of Staphylococcus aureus in atopic eczema: treatment strategies. Journal of the European Academy of Dermatology and Venereology, 7(S1).
- Cyclosporine in severe childhood atopic dermatitis: A multicenter study. J AM ACAD DERMATOL, 34(6), 1016-1021.
- Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment.. Hum Genet, 97(6), 723-726.
- Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Human Genetics, 97(6), 723-726.
- NOVEL GENETIC ASSOCIATION OF AN IL-1-BETA GENE VARIATION AT-+3953, SUSCEPTIBILITY TO PSORIASIS AND IL-1-BETA PROTEIN-PRODUCTION. J INVEST DERMATOL, 105(3), 453-453.
- TREATMENT OF GROVERS-DISEASE WITH CALCIPOTRIOL (DOVONEX(R)). BRIT J DERMATOL, 132(5), 832-833.
- Comparative genetic association of human leukocyte antigen class II and tumor necrosis factor-alpha with dermatitis herpetiformis.. J Invest Dermatol, 104(5), 856-858.
- An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata.. J Invest Dermatol, 104(5 Suppl), 15S-16S.
- Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus.. Hum Genet, 94(4), 407-410.
- ASSOCIATION OF THE INTERLEUKIN ONE RECEPTOR ANTAGONIST GENE POLYMORPHISM WITH LICHEN-SCLEROSUS. J INVEST DERMATOL, 103(3), 408-408.
- Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus.. Arthritis Rheum, 37(9), 1380-1385.
- Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene.. J Invest Dermatol, 103(3), 387-390.
- An audit of the value of patch testing: the patient's perspective.. Contact Dermatitis, 30(4), 214-216.
- Psoriasis and interleukin-1. A translation.. J R Coll Physicians Lond, 27(4), 366.
- Cytokine gene polymorphisms in inflammatory dermatoses. Journal of Dermatological Science, 6(1), 18-18.
- Cytokine gene activation across the advancing edge of psoriatic plaques. Journal of Dermatological Science, 6(1), 2-2.
- INTERLEUKIN ONE RECEPTOR ANTAGONIST POLYMORPHISM - ALLELIC ASSOCIATION WITH INFLAMMATORY DERMATOSES. J INVEST DERMATOL, 100(4), 448-448.
- GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. J INVEST DERMATOL, 100(4), 522-522.
- GENETICS OF INTERLEUKIN ONE RECEPTOR ANTAGONIST IN INFLAMMATORY SKIN DISEASES. CLIN RES, 41(2), A179-A179.
- A single-blind comparison of topical erythromycin/zinc lotion and oral minocycline in the treatment of acne vulgaris. Journal of Dermatological Treatment, 4(3), 119-122.
- Allergic contact dermatitis from resin-reinforced plaster.. Contact Dermatitis, 28(1), 40-41.
- Phytophotodermatitis mimicking child abuse.. Eur J Pediatr, 152(4), 291-292.
- Nickel sensitivity: the influence of ear piercing and atopy.. Br J Dermatol, 126(1), 16-18.
- PYODERMA-GANGRENOSUM. BRIT MED J, 303(6807), 925-925.
- Occupational vitiligo and contact sensitivity to para-tertiary butyl catechol.. Contact Dermatitis, 25(3), 200-201.
- Pruritus ani, piperazine, and thrombocytopenia.. BMJ, 301(6765), 1398-1398.
- A stimulator of murine haemopoietic stem cell proliferation produced by human fetal liver cells. British Journal of Haematology, 63(4), 775-783.
- Regulation of murine granulocyte-macrophage progenitor cell and haemopoietic stem cell proliferation by factors produced in human fetal liver. Leukemia Research, 6(4), 553-565.
- The regulation of the haematopoietic stem cell compartment in foetal liver.. Progress in clinical and biological research, 59 B, 277-285.
- Regulation of the growth fraction of CFU-S by an inhibitor produced by bone marrow. Leukemia Research, 5(1), 101-105.
- The control of haematopoietic stem cell proliferation by humoral factors.. Progress in clinical and biological research, 59 B, 269-276.
- Changes in the growth fraction of haempoietic stem cells following treatment with normal rat bone marrow extract. Cell and Tissue Kinetics, 13(2), 211-212.
- Novel biophysical skin biomarkers discriminate topical anti‐inflammatory treatments based on their potential for local adverse effects. JEADV Clinical Practice.
- Refractory pyoderma gangrenosum in Caucasian adolescent with Takayasu arteritis and life‐threatening infections. JEADV Clinical Practice.
- Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Dermatology and Therapy.
- Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT. Health Technology Assessment, 1-116.
- Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. American Journal of Clinical Dermatology.
- Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure. SKIN The Journal of Cutaneous Medicine, 8(2), s379-s379.
- Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks. SKIN The Journal of Cutaneous Medicine, 8(2), s377-s377.
- Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. Acta Dermato-Venereologica, 104, adv13467-adv13467.
- Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review. Drug Design, Development and Therapy, Volume 18, 277-289.
- Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis. Pediatric Drugs.
- Long-Term Efficacy of Abrocitinib in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND. SKIN The Journal of Cutaneous Medicine, 8(1), s329-s329.
- Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial. SKIN The Journal of Cutaneous Medicine, 8(1), s323-s323.
- Maintenance of an Acidic Skin Surface with a Novel Zinc Lactobionate Emollient Preparation Improves Skin Barrier Function in Patients with Atopic Dermatitis. Dermatology and Therapy.
- Characterisation of skin barrier defects in atopic dermatitis patients using Infrared Spectroscopy. Clinical and Experimental Dermatology.
- Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1. American Journal of Clinical Dermatology.
- Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, 7(2), s140-s140.
- The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, 7(2), s139-s139.
- Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis. JAMA Dermatology.
- The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, 6(6), s77-s77.
- Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews, 2022(11).
- A real‐world retrospective observational study exploring NHS resource use in England for the management of moderate‐to‐severe atopic dermatitis in secondary care for children and adolescents. Pediatric Dermatology.
- Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data. Pediatric Dermatology.
- Skin care interventions in infants for preventing eczema and food allergy: a Cochrane systematic review and individual participant data meta‐analysis. Clinical & Experimental Allergy.
- Skin care interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews.
- Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Food Allergies. SKIN The Journal of Cutaneous Medicine, 5(1), s12-s12.
- Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 5(1), s9-s9.
- Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Comorbid Allergic Rhinitis. SKIN The Journal of Cutaneous Medicine, 5(1), s13-s13.
- The effect of water hardness on atopic eczema and skin barrier function: A systematic review and meta‐analysis. Clinical & Experimental Allergy.
- Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 4(6), s98-s98.
- Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 4(6), s104-s104.
- European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology.
- Skincare interventions in infants for preventing eczema and food allergy. Cochrane Database of Systematic Reviews.
- Topical oils for the prevention or treatment of dry skin in term infants. Cochrane Database of Systematic Reviews.
- Topical oils for the prevention or treatment of dry skin in term infants. Cochrane Database of Systematic Reviews.
- Atopic dermatitis epidemiology and unmet need in the United Kingdom. Journal of Dermatological Treatment. View this article in WRRO
- Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology. View this article in WRRO
- Response to: Letter to the Editor Regarding “An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-Vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1”. Dermatology and Therapy.
- Randomized controlled pilot trial with ion‐exchange water softeners to prevent eczema (SOFTER trial). Clinical & Experimental Allergy.
Chapters
- pH in Atopic Dermatitis, pH of the Skin: Issues and Challenges (pp. 95-107). S. Karger AG
- Neonatal Skin Care and Toxicology In Eichenfield LF, Frieden IJ, Zaenglein A & Mathes E (Ed.), Neonatal and Infant Dermatology (pp. 46-56). Saunders
- Current and Future Trends: Skin Diseases and Treatment In Benson HAE & Watkinson AC (Ed.), Topical and Transdermal Drug Delivery Wiley
- The Skin Barrier in Atopic Dermatitis. In Irvine A, Hoeger P & Yan A (Ed.), Textbook of Pediatric Dermatology, UK: Blackwell Publishing Ltd..
- Skin Barrier Dysfunction in Atopic Dermatitis, Basic and Clinical Dermatology (pp. 211-240). Informa Healthcare
- Epidermal Barrier Dysfunction in Atopic Dermatitis In Rawlings L (Ed.), Skin Moisturization USA: Informa Healthcare USA Inc..
Conference proceedings papers
- Children with atopic dermatitis respond more rapidly to dupilumab treatment in comparison to adolescents and adults. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 144(8) (pp S48-S48)
- 55 Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology, Vol. 143(11) (pp S342-S342)
- 410 Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis. British Journal of Dermatology, Vol. 188(Supplement_3)
- 383 Integrated safety analysis of abrocitinib in 635 adolescent patients with moderate-to-severe atopic dermatitis with over 1000 patient-years of exposure. British Journal of Dermatology, Vol. 188(Supplement_3)
- 437 Treatment-emergent adverse events in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis treated with dupilumab in an open-label extension clinical trial. British Journal of Dermatology, Vol. 188(Supplement_3)
- 411 Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis. British Journal of Dermatology, Vol. 188(Supplement_3)
- 337 Dupilumab treatment is not associated with an increased overall risk of infections in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis. British Journal of Dermatology, Vol. 188(Supplement_2)
- Dupilumab Treatment is Not AssociatedWith an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 yearsWithModerate-to-Severe Atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 100-101)
- Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB100-AB100)
- SAFETY OF TRALOKINUMAB IN PAEDIATRIC PATIENTS AGED 12-17 WITH MODERATE-TO-SEVERE AROPIC DERMATITIS: RESULTS FROM THE PHASE 3 ECZTRA 6 TRIAL. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 58-58)
- Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB221-AB221)
- PROGRESSIVE AND SUSTAINED DISEASE CONTROL IN PATIENTS WITH ATOPIC DERMATITIS (AD) AGED 12-17 YEARS TREATED WITH TRALOKINUMAB FOR 52 WEEKS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 30-30)
- Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB190-AB190)
- LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
- LONG-TERM DUPILUMAB TREATMENT IS NOT ASSOCIATED WITH AN INCREASED OVERALL RISK OF INFECTIONS IN PATIENTS AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN AN OPENLABEL EXTENSION STUDY. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 54-54)
- Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB62-AB62)
- Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 21 (pp 77-77)
- EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 103 (pp 53-53)
- Dupilumab treatment normalizes skin barrier function and improves patient-reported outcomes in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 143(11) (pp S342-S342)
- Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 89(3) (pp AB40-AB40)
- Sequence of improvement in atopic dermatitis signs and symptoms in patients aged 6 months to 17 years treated with dupilumab. ALLERGY, Vol. 78 (pp 196-196)
- Dupilumab treatment normalizes skin barrier function and symptoms in children aged 6-11 years with moderate-to-severe atopic dermatitis. ALLERGY, Vol. 78 (pp 194-194)
- Allergy profile for patients receiving dupilumab for severe atopic dermatitis. ALLERGY, Vol. 78
- Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1014-1014)
- Dupilumab treatment is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels in children aged 6 to 11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 52(8) (pp 1059-1059)
- Long-term efficacy of abrocitinib after initial successful treatment in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 72-72)
- A randomized controlled trial assessing the effectiveness and safety of ciclosporin vs. methotrexate in the treatment of severe atopic eczema in children and young people: the TREatment of severe Atopic eczema Trial (TREAT). BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 13-14)
- Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E173-E173)
- Efficacy and safety of dupilumab in children aged 6-11 years with inadequately controlled severe atopic dermatitis: results from an open-label extension trial up to 1 year. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E159-E160)
- Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E90-E91)
- Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 142(8) (pp B17-B17)
- Dupilumab treatment improved sleep quality in moderate-to-severe atopic dermatitis in children aged 6 months-5 years and their caregivers. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E112-E113)
- A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E96-E96)
- Dupilumab treatment improves health-related quality of life in children aged 6 months-5 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187(3) (pp E104-E105)
- Efficacy and safety of dupilumab in children aged >= 6 months to < 6 years with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 12-12)
- Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 69-69)
- Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 187 (pp 79-79)
- Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase III ECZTRA 6 trial. BRITISH JOURNAL OF DERMATOLOGY, Vol. 186(4) (pp E145-E146)
- EFFECTS OF EMOLLIENT CREAMS ON THE SKIN BARRIER OF PATIENTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 102 (pp 35-36)
- 161 52-Week Laboratory Safety Findings From an Open-Label Extension Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE) (pp a68.2-a6a69)
- Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1659-1659)
- Dupilumab treatment leads to mild transient increases in eosinophil levels without clinical relevance in children aged 6-11 years with severe atopic dermatitis. CLINICAL AND EXPERIMENTAL ALLERGY, Vol. 51(12) (pp 1687-1688)
- Fifty-two-week laboratory safety findings from an open-label extension study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E121-E121)
- Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E115-E116)
- 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
- Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB120-AB120)
- Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6-11 years with severe atopic dermatitis (AD). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB136-AB136)
- Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 141(5) (pp S84-S84)
- LABORATORY SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS AGED >= 6-< 12 YEARS WITH SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 3 TRIAL (LIBERTY AD PEDS). ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 59-59)
- LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN A PHASE 3 OPEN-LABEL EXTENSION TRIAL (LIBERTY AD PED-OLE) IN PATIENTS AGED >= 6 TO < 12 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 60-60)
- Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 14-14)
- Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E110-E110)
- Impact of abrocitinib on itch, sleep, skin pain and psychological stress in patients with moderate-to-severe atopic dermatitis: pooled analysis from JADE monotherapy trials. BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E72-E73)
- Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB141-AB141)
- Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 85(3) (pp AB97-AB97)
- The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19 (pp 56-56)
- Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E65)
- Early changes in patient-relevant endpoints in three tralokinumab pivotal phase III trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 184(3) (pp E64-E64)
- LOWERING SKIN SURFACE PH WITH A TOPICAL ZINC LACTOBIONATE PREPARATION CONTAINING PHYSIOLOGIC LIPIDS IMPROVES SKIN BARRIER STRUCTURE AND FUNCTION IN ADULTS WITH ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 51-51)
- Laboratory safety of dupilumab in paediatric patients aged >= 6 to < 12 years with severe atopic dermatitis: results from a phase III trial (LIBERTY AD PEDS). BRITISH JOURNAL OF DERMATOLOGY, Vol. 185(3) (pp E122-E123)
- A RANDOMISED CONTROLLED TRIAL OF DAILY EMOLLIENT DURING INFANCY FOR PREVENTING ECZEMA - RESULTS OF THE BEEP TRIAL. ACTA DERMATO-VENEREOLOGICA, Vol. 101 (pp 7-8)
- An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB71-AB71)
- Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 83(6) (pp AB39-AB39)
- The use of systemic immunomodulatory agents in the treatment of children and adolescents with atopic eczema: lessons from the UK-Irish Atopic Eczema Systemic Therapy (A-STAR) Register. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-148)
- Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 140(7) (pp S60-S60)
- Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183(4) (pp E105-E106)
- A real-world observational study to describe National Health Service resource use for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents aged 6-17 years. BRITISH JOURNAL OF DERMATOLOGY, Vol. 183 (pp 147-147)
- 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology, Vol. 139(5) (pp s104-s104), 8 May 2019 - 11 May 2019. View this article in WRRO
- Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 139(5) (pp S104-S104)
- Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 17 (pp 116-116)
- View this article in WRRO Quantification of natural moisturizing factors at the skin surface using a portable infrared spectrometer device: a pilot, calibration model. BRITISH JOURNAL OF DERMATOLOGY, Vol. 179(1) (pp E35-E36)
- An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 155-155)
- An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 177 (pp 67-68)
- Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 15 (pp 79-79)
- Characterizing the microcirculation of atopic dermatitis using angiographic optical coherence tomography. Proceedings of SPIE, Vol. 10037 View this article in WRRO
- DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN ATOPIC DERMATITIS PATIENTS INADEQUATELY CONTROLLED, INTOLERANT, OR INADVISABLE FOR CYCLOSPORINE-A. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, Vol. 119(5) (pp S94-S95)
- Characterisation of the skin barrier defect in atopic dermatitis using in vivo ATR-FTIR spectroscopy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 136(9) (pp S182-S182)
- A pilot, assessor-blinded, randomized controlled trial of topical oils for neonatal skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 173 (pp 153-153)
- The effect of a complex emollient cream containing 5% urea, ceramide 3 and lactic acid, compared with a simple emollient, on the skin barrier in older people with dry skin. BRITISH JOURNAL OF DERMATOLOGY, Vol. 171 (pp 57-58)
- Feasibility study of Barrier Enhancement For Eczema Prevention (BEEP). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E8-E9)
- Noninvasive assessment of the lipid structure and water holding properties of the stratum corneum in vivo by ATR-FTIR using a fibre optic probe in patients with atopic dermatitis and healthy controls. BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E29-E29)
- A protocol for a randomized controlled trial to determine whether application of emollient from birth can prevent eczema in high-risk children (BEEP Trial). BRITISH JOURNAL OF DERMATOLOGY, Vol. 170(6) (pp E32-E32)
- A difficult case of atopic eczema: useful learning points. BRITISH JOURNAL OF DERMATOLOGY, Vol. 169 (pp 120-120)
- Chymotrypsin-like protease activity in the stratum corneum is increased in atopic dermatitis and upon washing with soap. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 68(4) (pp AB172-AB172)
- Skin barrier breakdown in atopic dermatitis: the effect of topical products. INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Vol. 34(4) (pp 363-364)
- Vitamin D supplementation improves atopic dermatitis and atopic dermatitis complicated by eczema herpeticum. BRITISH JOURNAL OF DERMATOLOGY, Vol. 167 (pp 127-127)
- A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 115-115)
- A randomized comparison of aqueous cream and Oilatum (R) Junior bath additive on skin barrier function in atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 165 (pp 44-45)
- Patch testing is a useful investigation in children with eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 125-125)
- Breakdown of the skin barrier induced by aqueous cream: implications for the management of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 115-116)
- Skin protease inhibitors: a new treatment for atopic dermatitis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 161 (pp 30-31)
- Skin protease inhibitors: A new treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 60(3) (pp AB67-AB67)
- Contamination of emollient creams and ointments with Staphylococcus aureus in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 114-114)
- Vitamin A metabolic pathway inhibition: a new therapeutic approach to treating psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 159 (pp 118-118)
- Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - Implications for therapy. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 127 (pp S45-S45)
- Severe alopecia areata is associated with a functional polymorphism in the PTPN22 gene. IMMUNOLOGY, Vol. 120 (pp 70-70)
- The effects of topical corticosteroids and pimecrolimus skin barrier function, gene expression, and topical drug penetration in atopic eczema and unaffected controls. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 56(2) (pp AB69-AB69)
- Reduced and abnormal proteolysis of corneodesmosomal proteins in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 126 (pp 116-116)
- A study on the effect of genetic variants of the autoimmune regulator (AIRE) promoter, on AIRE activity and downstream Aire-regulated genes. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 250-250)
- A synonymous single nucleotide polymorphism in human cystatin A, a candidate gene in the PSORS5 locus, confers susceptibility to psoriasis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 155(1) (pp 235-235)
- Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 54(3) (pp AB3-AB3)
- Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 605-605)
- Treatment of atopic dermatitis from a skin barrier perspective. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 125(3) (pp 611-611)
- Skin barrier damage: Cause or consequence of atopic dermatitis?. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, Vol. 52(3) (pp P9-P9)
- An audit of adverse drug reactions to aqueous cream in children with atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 151 (pp 57-58)
- Abnormal proteolysis of corneodesmosin in psoriatic skin. JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol. 121(6) (pp 1568-1568)
- Role of variants within genes regulating the skin barrier in the pathogenesis of atopic eczema. BRITISH JOURNAL OF DERMATOLOGY, Vol. 149 (pp 4-4)
- Genetic analysis of the autoimmune regulator (aire) gene: potential role of aire in susceptibility to alopecia universalis. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 849-850)
- Alopecia areata: age at onset, atopy & disease associations. BRITISH JOURNAL OF DERMATOLOGY, Vol. 148(4) (pp 866-867)
- Introduction. Journal of Investigative Dermatology Symposium Proceedings, Vol. 4(3) (pp 199-199)
- The role of in atopic eczema: treatment strategies. Journal of the European Academy of Dermatology and Venereology, Vol. 7 (pp S31-S37)
- Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, Vol. 6(2) (pp s29-s29)
Reports
Posters
- 41343 Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis.
- 41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers.
- 43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND.
- 42924 Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial.
- 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis.
- P24 Emollient use and effects on cutaneous allergen reactions: a preliminary study.
- P40 Dupilumab treatment restores skin barrier function in lesional and nonlesional skin of patients with atopic dermatitis and improves patient-reported outcomes.
- P73 Laboratory safety from a 16-week phase III study of dupilumab in patients aged 6 months–5 years with moderate-to-severe atopic dermatitis.
- P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND.
- 392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis.
- 353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay.
- 345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis.
- 34326 Real-world analysis of skin infections and antimicrobial use among patients with atopic dermatitis before and after initiation of dupilumab treatment.
- 34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis.
- 33569 Optimization of common hand cleansers for protection from viral spread and occupational hand dermatoses.
- 34655 Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program.
- 33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD).
- LB946 Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment.
- 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial.
- 27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6–11 years with severe atopic dermatitis (AD).
- 26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD).
- 26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE).
- Teaching interests
-
My teaching interests within The University include medical undergraduate lecturing and in-clinic training plus postgraduate researcher training and mentoring. I also lecture to related courses at other universities, such as the MSc in Dermatology at Cardiff and at major international and national conferences in the field of dermatology. In addition I undertake a large number of atopic eczema related educational presentations at local, national and international level to a wide range of audiences including; pharmacists, general practitioners, hospital nurses, community nurses, midwives, paediatricians, practice nurses and patient support charities (e.g. National Eczema Society, Skin Care Campaign and Psoriasis Association).
Education of Children with Skin Diseases:
I have developed a special interest in `translating´ the complex pathophysiology of skin disease into cartoons and language that can be understood by a child of six. I presented these to the National Eczema Society and the Skin Care Campaign. I have written papers for these charities describing the content of the lectures, for example Cork et al 2000; 2002 "Skin Wars". I use the cartoons in my clinics to teach children and their parent about skin diseases. The medical students that sit-in during my clinics, suggested I incorporated the "Skin Wars" cartoons into their lectures because they made dermatology exciting. The "Skin Wars" cartoons have been disseminated to many other dermatology departments. I have assigned all commercial profits from use of the "Skin Wars" cartoons to the National Eczema Society. The "Skin Wars" teaching approach was cited as being an innovative approach to education by the judges in the Hospital Doctor Dermatology Team of the Year Awards, which our paediatric dermatology team won in 2001. This teaching method was also highlighted in the National Eczema Society Health Care Professionals Award 2004.
- Professional activities and memberships
-
- Member of the National Institute of Clinical Excellence (NICE) clinical guideline development group for the treatment of Atopic Eczema in children.
- Advisor, Lecturer and developer of educational materials for the National Eczema Society, Skin Care Campaign, Psoriasis Association and Allergy UK.
- Wellcome Trust Translational Grants Reviewer & Expert Panel member.
- Grant Reviewer, British Skin Foundation, Psoriasis Association and Wellcome Trust.
- Fellow of the Royal College of Physicians, London and Edinburgh.
- Member of British Association of Dermatologists.
- Member of European Academy of Dermatology and Venereology.
- Member of British Society for Investigative Dermatology.
- Member of European Society for Dermatological Research.
- Member of British Society for Paediatric Dermatology.
- Member of Dowling Dermatology Society.
- Professional Member of the National Eczema Society.
- Member of The Council (board) of the Psoriasis Association.
- South Yorkshire Biotech Enterprise Network (SYBEN): York Pharma – Biotech company of the year, 2006.
- Yorkshire Forward Bioscience Yorkshire Annual Awards: Molecular Skin Care: Recognised for Outstanding Achievements in Bioscience. Awarded to the company who has made the greatest advances in Yorkshire in 2005.
- Leader of the team awarded ‘Health Care Professional Team of the Year’ by the National Eczema Society in 2004.
- Leader of the team awarded ‘Hospital Doctor Dermatology Team of the Year’ 2001.
- Enquiries
For Teaching & Academic Supervisory Enquiries, Post-Graduate and Undergraduate (i.e. PATs) please email:
Les Hunter & cc to Prof. Michael J. Cork
For Research Enquiries (including Pharmacological, Cosmetic & Academic) please email: Les Hunter & cc to Prof. Michael J. Cork
For Children’s Clinical NHS Enquiries please email: Elaine Cox & cc to Prof. Michael J. Cork
For Adult Clinical NHS Enquiries please email: Lucy Lowe & cc to Prof. Michael J. Cork